Oncology · Combination TherapyTrial Updateclinicalmid-term

Phase Ib Trial of M1774 and ZEN-3694 in Recurrent Ovarian and Endometrial Cancer

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/30/2026, 6:06:04 AM

Assessment confidence: 69% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing phase Ib trial of M1774 and ZEN-3694 could significantly impact treatment options for recurrent ovarian and endometrial cancers. Positive outcomes may enhance the competitive positioning of these therapies in the oncology market, potentially leading to new collaborations and revenue streams for involved entities. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 24 ranked evidence items (13 high-relevance).

Strategic Assessment

Positive trial results may enhance the portfolio of the National Cancer Institute and its collaborators, potentially leading to new treatment options in oncology. The strongest clinical anchor is Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer (ClinicalTrials.gov), entity match (zen-3694); patient population match (recurrent). In Oncology · Combination Therapy, 4 regulatory and 5 competitive items passed relevance filtering for ZEN-3694.

Competitive Pressure

The most relevant competitive pressure comes from Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) (Merck) — sponsor/company relevance (merck). Secondary pressure from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC.

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (approval). If the trial demonstrates safety and efficacy, it may pave the way for expedited regulatory pathways and new indications for these drugs, impacting their approval timelines.

Key Risks

Elevated medium regulatory exposure for ZEN-3694 could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Successful trial results could lead to increased market share for M1774 and ZEN-3694, positioning them as preferred treatment options in a competitive oncology landscape.
Upside for ZEN-3694 may improve if Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Upside for ZEN-3694 may improve if Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma (ClinicalTrials.gov) delivers favorable follow-through.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for safety and efficacy outcomes, as well as any announcements regarding further development plans.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
ClinicalTrials.govhigh relevance
Entity match (zen-3694); Patient population match (recurrent)
FDA document
View source
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ClinicalTrials.govhigh relevance
Entity match (national cancer institute); Patient population match (recurrent)
FDA document
View source
Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma
ClinicalTrials.govhigh relevance
Entity match (national cancer institute); Patient population match (recurrent)
FDA document
View source
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
ClinicalTrials.govhigh relevance
Patient population match (recurrent)
FDA document
View source
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)
Phase I/II Trial of Lentiviral Gene Transfer for XSCID in Children Over Two Years
Humanexa Signalsmedium relevance
Moderate corpus alignment
Bristol-Myers Squibb Evaluates Pumitamig vs Pembrolizumab in NSCLC Trial
Humanexa Signalsmedium relevance
Moderate corpus alignment

Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

ZEN-3694
National Cancer Institute
recurrent ovarian cancer
recurrent endometrial cancer
NRG Oncology

Commercial impact

medium

Successful trial results could lead to increased market share for M1774 and ZEN-3694, positioning them as preferred treatment options in a competitive oncology landscape.

Regulatory impact

medium

If the trial demonstrates safety and efficacy, it may pave the way for expedited regulatory pathways and new indications for these drugs, impacting their approval timelines.

What to watch

Monitor trial results for safety and efficacy outcomes, as well as any announcements regarding further development plans.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.